参考文献/References:
[1] Hassoun PM. Pulmonary arterial hypertension [J]. N Engl J Med,2021,385(25):2361-2376.
[2] D?rner T,Furie R. Novel paradigms in systemic lupus erythematosus[J]. Lancet,2019,393(10188):2344-2358.
[3] Zhao J,Wang Q,Liu Y,et al. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases:a cohort study in China[J]. Int J Cardiol ,2017,236:432-437.
[4] Kim JS,Kim D,Joo YB,et al. Factors associated with development and mortality of pulmonary hypertension in systemic lupus erythematosus patients[J]. Lupus,2018,27(11):1769-1777.
[5] 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志,2021,101(1):11-51.
[6] Tselios K,Urowitz MB. Cardiovascular and pulmonary manifestations of systemic lupus erythematosus[J]. Curr Rheumatol Rev,2017,13(3):206-218.
[7] Chen HA,Hsu TC,Yang SC,et al. Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study[J]. Arthritis Res Ther,2019,21(1):82.
[8] Stout KK,Daniels CJ,Aboulhosn JA,et al. 2018 AHA/ACC Guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. J Am Coll Cardiol,2019,73(12):e81-e192.
[9] Collins N,Bastian B,Quiqueree L,et al. Abnormal pulmonary vascular responses in patients registered with a systemic autoimmunity database: pulmonary hpertension Assessment and Screening Evaluation using stress echocardiography (PHASE-I)[J]. Eur J Echocardiogr ,2006,7(6):439-446.
[10] Konstantinides SV,Meyer G,Becattini C,et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)[J]. Eur Respir J,2019,54(3)
[11] Nakazawa T,Watanabe Y,Hori Y,et al. Lung perfused blood volume images with dual-energy computed tomography for chronic thromboembolic pulmonary hypertension: correlation to scintigraphy with single-photon emission computed tomography[J]. J Comput Assist Tomogr,2011,35(5):590-595.
[12] Shahin Y,Alabed S,Alkhanfar D,et al. Quantitative CT evaluation of small pulmonary vessels has functional and prognostic value in pulmonary hypertension[J]. Radiology,2022:210482.
[13] 孙学彪,刘敏. 心脏MR评估肺动脉高压右心室结构及预后的研究进展[J]. 中华放射学杂志,2021,55(9):993-996.
[14] Han QJ,Witschey WR,Fang-Yen CM,et al. Altered right ventricular kinetic energy work density and viscous energy dissipation in patients with pulmonary arterial hypertension: A pilot Study using 4D flow MRI[J]. PLoS One,2015,10(9):e0138365.
[15] Ray JC,Burger C,Mergo P,et al. Pulmonary arterial stiffness assessed by cardiovascular magnetic resonance imaging is a predictor of mild pulmonary arterial hypertension[J]. Int J Cardiovasc Imaging,2019,35(10):1881-1892.
[16] Luo S,Dou WQ,Schoepf UJ,et al. Cardiovascular magnetic resonance imaging in myocardial involvement of systemic lupus erythematosus[J]. Trends Cardiovasc Med,2022 Feb 10:S1050-1738(22)00025-1. doi: 10.1016/j.tcm.2022.02.002.
[17] Sch?fer M,Barker AJ,Kheyfets V,et al. Helicity and vorticity of pulmonary arterial flow in patients with pulmonary hypertension: quantitative analysis of flow formations[J]. J Am Heart Assoc ,2017,6(12):e007010.
[18] Reiter G,Reiter U,Kovacs G,et al. Blood flow vortices along the main pulmonary artery measured with MR imaging for diagnosis of pulmonary hypertension[J]. Radiology,2015,275(1):71-79.
[19] Remy-Jardin M,Ryerson CJ,Schiebler ML,et al. Imaging of pulmonary hypertension in adults: A position paper from the fleischner society[ J]. Radiology,2021,298(3):531-549.
[20] Rajaram S,Swift AJ,Condliffe R,et al. CT features of pulmonary arterial hypertension and its major subtypes:a systematic CT evaluation of 292 patients from the ASPIRE Registry[J]. Thorax,2015,70(4):382-387.
[21] Dara A,Arvanitaki A,Theodorakopoulou M,et al. Non-invasive assessment of endothelial dysfunction in Pulmonary arterial hypertension[J]. Mediterr J Rheumatol ,2021,32(1):6-14.
[22] Kagami K,Harada T,Yamaguchi K,et al. Association between lung ultrasound B-lines and exercise-induced pulmonary hypertension in patients with connective tissue disease[J]. Echocardiography,2021,38(8):1297-1306.
[23] 李梦涛,王迁,赵久良,等.中国成人系统性红斑狼疮相关肺动脉高压诊治共识[J].中华内科杂志,2015,54(1):81-86.
[24] Wang L,Xiong C,Li M,et al. Assessment of lung glucose uptake in patients with systemic lupus erythematosus pulmonary arterial hypertension: a quantitative FDG-PET imaging study[J]. Ann Nucl Med,2020,34(6):407-414.
[25] Borjas-Howard JF,Leeuw K,Rutgers A,et al. Risk of recurrent venous thromboembolism in autoimmune diseases:a systematic review of the literature[ J]. Semin Thromb Hemost,2019,45(2):141-149.
[26] Courtwright AM,El-Chemaly S,Dellaripa PF,et al. Survival and outcomes after lung transplantation for non-scleroderma connective tissue-related interstitial lung disease[J]. J Heart Lung Transplant,2017,36(7):763-769.
[27] Yang X,Wei D,Liu M,et al. Survival and outcomes after lung transplantation for connective tissue disease-associated interstitial lung diseases[J]. Clin Rheumatol,2021,40(9):3789-3795.
[28] Ovadia M,Tsifansky MD. V/Q-SPECT scintigraphy in pulmonary hypertension:predictor of mortality versus trigger for transplant,a british versus american perspective[J ]. JACC Cardiovasc Imaging,2018,11(10):1494-1498.
[29] Qian J,Wang Y,Huang C,et al. Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension:a PRISMA-compliant systematic review and meta-analysis[J]. Autoimmun Rev ,2016,15(3):250-257.
[30] Guo X,Lai J,Wang H,et al. Predictive value of non-invasive right ventricle to pulmonary circulation coupling in systemic lupus erythematosus patients with pulmonary arterial hypertension[J]. Eur Heart J Cardiovasc Imaging,2021,22(1):111-118.
[31] Xiong J,Yu S,Liu R,et al. The role of conjunctival microvasculation combined with echocardiography in evaluating pulmonary arterial hypertension in systemic lupus erythematosus[J]. Dis Markers,2021,2021:2135942.
[32] Li X,Zhang C,Sun X,et al. Prognostic factors of pulmonary hypertension associated with connective tissue disease: pulmonary artery size measured by chest CT[J]. Rheumatology (Oxford),2020,59(11):3221-3228.
[33] Guo X,Lai J,Wang H,et al. Predictive value of pulmonary arterial compliance in systemic lupus erythematosus patients with pulmonary arterial hypertension[J]. Hypertension,2020,76(4):1161-1168.
[34] Mielniczuk LM,Birnie D,Ziadi MC,et al. Relation between right ventricular function and increased right ventricular [18F]fluorodeoxyglucose accumulation in patients with heart failure[J]. Circ Cardiovasc Imaging,2011,4(1):59-66.
[35] Kazimierczyk R,Szumowski P,Nekolla SG,et al. Prognostic role of PET/MRI hybrid imaging in patients with pulmonary arterial hypertension[J]. Heart,2021,107(1):54-60.
[36] Baggen VJ,Leiner T,Post MC,et al. Cardiac magnetic resonance findings predicting mortality in patients with pulmonary arterial hypertension: a systematic review and meta-analysis[J]. Eur Radiol,2016,26(11):3771-3780.
[37] Argentiero A,Muscogiuri G,Rabbat MG,et al. The Applications of artificial intelligence in cardiovascular magnetic resonance-a comprehensive review[J]. J Clin Med,2022,11(10):2866.
[38] Willemink MJ,Persson M,Pourmorteza A,et al. Photon-counting CT:technical principles and clinical prospects[J]. Radiology,2018,289(2):293-312.
[39] Kwon JM,Kim KH,Medina-Inojosa J,et al. Artificial intelligence for early prediction of pulmonary hypertension using electrocardiography[J]. J Heart Lung Transplant,2020,39(8):805-814.
相似文献/References:
[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(12):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(12):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(12):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(12):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[5]徐学萍 汪汉 蔡琳.结缔组织病相关心脏瓣膜病[J].心血管病学进展,2019,(9):1267.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.021]
XU Xueping,WANG Han,CAI Lin.Connective Tissue Disease-associated Valvular Heart Disease[J].Advances in Cardiovascular Diseases,2019,(12):1267.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.021]
[6]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(12):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[7]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(12):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[8]秦莉,张艺文,杨晓倩,等.系统性红斑狼疮合并心力衰竭的危险因素及管理[J].心血管病学进展,2020,(3):264.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.012]
QIN Li,ZHANG Yiwen,YANG Xiaoqian,et al.Risk Factors and Management of Heart Failure in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2020,(12):264.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.012]
[9]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(12):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[10]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(12):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]